Mikhail Blagosklonny is a professor of Oncology at the Roswell Park Cancer Institute. Mikhail is a scientist who studies Aging and Cancer. He went to the First Pavlov State Medical University of St. Petersburg where he earned an MD in Internal Medicine. Mikhail also earned a Ph.D. in Experimental Medicine and Cardiology from the same University. Mikhail was made the associate professor of medicine at New York Medical College in 2002. The college is in Valhalla, New York. He later went on to Ordway Research Institute where he served as the senior scientist. Mikhail joined Roswell Park Cancer Institute as the Professor of Oncology in 2009. The experience and skills that he had gained in the different places he had worked made him become an excellent professor. His research interests include Biogerontology (underlying mechanisms of aging), anti-aging drugs, cancer, and targeted cancer therapies that guard the healthy cells against getting damaged.
Mikhail Blagosklonny works as the editor-in-chief of Oncotarget and Cell Cycle. He is also the associate editor of cancer biology and therapy. Mikhail is in the Cell Death and Differentiation editorial board. Mikhail has come up with a hypothesis regarding TOR Signaling potential role in cancer and aging. He proposed using Rapamycin. Rapamycin is a popular drug used in the treatment of cancer. Mikhail suggested this as a possible treatment for lie extension. Mikhail Blagosklonny has been categorized among the most passionate advocates of Rapamycin in longevity research. Mikhail research ranges from cellular and molecular biology to clinical investigations. It mainly includes signal transduction, ontogenesis, tumor suppressors, drug resistance for normal cells selective protection, apoptosis, cell cycle, anticancer therapeutics, and mitosis.
Mikhail is an author of aging hyperfunction theory. He also writes about cell cyclotherapy and chemotherapeutic engineering. Mikhail is known for his keen interest in oncology. He believes that it is possible to control aging and cancer. Mikhail Blagosklonny also believes that cancer can be cured and that is why he suggested the use of Rapamycin. Mikhail has 300 research articles, book chapters, and reviews that are published under his name. He is also an associate editor for PLOS ONE, the American Journal of Pathology, and International Journal of Cancer. Mikhail’s hard work and commitment are what have contributed to his achievement of becoming one of the biggest Oncology researchers in the world. He says that his love for humanity and the vision of seeing a disease-free community is what drove him into his field of work.